Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 16459340.
- Also identified by PMC identifier 1397778.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To find out what inpatients with advanced cancer who are receiving palliative care think about the effect of thromoprophylaxis on overall quality of life. Qualitative study using audiotaping of semistructured interviews. Regional cancer centre in Wales. 28 inpatients with advanced metastatic cancer receiving palliative care and low molecular weight heparin. Recurring themes on the effect of thromboprophylaxis on overall quality of life. Major emerging themes showed that patients knew about the risks of venous thromboembolism and the purpose of treatment with heparin. Media coverage had raised awareness about venous thromboembolism, and many had previous experience of thromboprophylaxis. All found low molecular weight heparin an acceptable intervention, and many said that it improved their quality of life by giving them a feeling of safety and reassurance. Antiembolic stockings were considered uncomfortable and had a negative impact on quality of life. Patients were concerned that because they had advanced disease they might not be eligible for thromboprophylaxis. Low molecular weight heparin is acceptable to inpatients with advanced cancer receiving palliative care and has a positive impact on overall quality of life. Antiembolic stockings are an unacceptable intervention in this patient group. Guidelines on thromboprophylaxis are urgently needed for palliative care inpatient units and hospices.
Medical subject headings
- Anticoagulants
- Heparin, Low-Molecular-Weight
- Neoplasms
- Palliative Care
- Patient Satisfaction
- Thromboembolism